Mesa Laboratories Inc
NASDAQ:MLAB
Mesa Laboratories Inc
NASDAQ:MLAB
Price:
121.56 USD
-0.54%
Market Closed
Updated:
May 21, 2024
Balance Sheet
Balance Sheet Decomposition
Mesa Laboratories Inc
Mesa Laboratories Inc
| Current Assets | 118.4m |
| Cash & Short-Term Investments | 28.2m |
| Receivables | 36m |
| Other Current Assets | 54.1m |
| Non-Current Assets | 623.4m |
| PP&E | 31.8m |
| Intangibles | 579m |
| Other Non-Current Assets | 12.7m |
| Current Liabilities | 44.2m |
| Accounts Payable | 4.6m |
| Accrued Liabilities | 23.5m |
| Other Current Liabilities | 16.2m |
| Non-Current Liabilities | 294.6m |
| Long-Term Debt | 233m |
| Other Non-Current Liabilities | 61.7m |
Balance Sheet
Mesa Laboratories Inc
Mesa Laboratories Inc
Currency: USD
| Mar-2014 | Mar-2015 | Mar-2016 | Mar-2017 | Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
6
|
2
|
6
|
6
|
6
|
10
|
81
|
264
|
49
|
33
|
|
| Cash Equivalents |
6
|
2
|
6
|
6
|
6
|
10
|
81
|
264
|
49
|
33
|
|
| Total Receivables |
9
|
12
|
15
|
14
|
14
|
13
|
21
|
24
|
41
|
43
|
|
| Accounts Receivables |
9
|
12
|
15
|
14
|
14
|
13
|
21
|
24
|
41
|
43
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
8
|
12
|
14
|
14
|
9
|
7
|
14
|
11
|
25
|
35
|
|
| Other Current Assets |
4
|
3
|
2
|
2
|
3
|
4
|
6
|
5
|
9
|
9
|
|
| Total Current Assets |
27
|
30
|
37
|
36
|
32
|
34
|
123
|
304
|
124
|
119
|
|
| PP&E Net |
8
|
10
|
17
|
26
|
24
|
22
|
25
|
24
|
39
|
37
|
|
| PP&E Gross |
8
|
10
|
17
|
26
|
24
|
22
|
25
|
24
|
39
|
37
|
|
| Accumulated Depreciation |
6
|
7
|
8
|
10
|
10
|
11
|
13
|
16
|
18
|
20
|
|
| Intangible Assets |
25
|
33
|
41
|
38
|
43
|
33
|
120
|
112
|
250
|
217
|
|
| Goodwill |
38
|
45
|
66
|
72
|
66
|
66
|
142
|
161
|
291
|
286
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
3
|
3
|
|
| Other Assets |
38
|
45
|
66
|
72
|
66
|
66
|
142
|
161
|
291
|
286
|
|
| Total Assets |
98
N/A
|
117
+20%
|
161
+37%
|
172
+7%
|
164
-4%
|
157
-4%
|
409
+161%
|
602
+47%
|
707
+18%
|
662
-6%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
3
|
3
|
2
|
2
|
3
|
3
|
5
|
8
|
6
|
|
| Accrued Liabilities |
6
|
5
|
8
|
7
|
8
|
11
|
16
|
18
|
26
|
23
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
3
|
3
|
1
|
2
|
2
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
2
|
4
|
10
|
6
|
6
|
7
|
7
|
10
|
14
|
14
|
|
| Total Current Liabilities |
10
|
15
|
24
|
17
|
17
|
24
|
26
|
33
|
48
|
43
|
|
| Long-Term Debt |
17
|
23
|
42
|
54
|
45
|
21
|
140
|
146
|
218
|
183
|
|
| Deferred Income Tax |
5
|
5
|
5
|
4
|
3
|
1
|
22
|
16
|
39
|
34
|
|
| Other Liabilities |
2
|
1
|
4
|
0
|
0
|
0
|
1
|
1
|
8
|
8
|
|
| Total Liabilities |
33
N/A
|
44
+32%
|
76
+74%
|
74
-3%
|
65
-12%
|
46
-30%
|
189
+316%
|
195
+3%
|
314
+61%
|
268
-14%
|
|
| Equity | |||||||||||
| Common Stock |
16
|
18
|
21
|
26
|
31
|
40
|
158
|
318
|
314
|
332
|
|
| Retained Earnings |
49
|
56
|
65
|
74
|
68
|
73
|
72
|
73
|
77
|
74
|
|
| Other Equity |
0
|
0
|
1
|
2
|
1
|
2
|
10
|
16
|
4
|
13
|
|
| Total Equity |
64
N/A
|
74
+14%
|
85
+15%
|
98
+15%
|
99
+2%
|
111
+12%
|
220
+98%
|
406
+85%
|
394
-3%
|
394
0%
|
|
| Total Liabilities & Equity |
98
N/A
|
117
+20%
|
161
+37%
|
172
+7%
|
164
-4%
|
157
-4%
|
409
+161%
|
602
+47%
|
707
+18%
|
662
-6%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
4
|
4
|
4
|
4
|
4
|
4
|
4
|
5
|
5
|
5
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
